CarBuzz on MSN
The Most Powerful Non-Turbocharged BMW Inline-Six Ever
Inline-six engines are the beating heart of a certain German automaker - here's the most powerful of them all.
Steven Ewing spent his childhood reading car magazines, making his career as an automotive journalist an absolute dream job. After getting his foot in the door at Automobile while he was still a ...
We had reports that a beastly new CSL edition of the BMW M4 would arrive this May. It’s now May, and BMW has just unleashed a new M4 CSL, a car that — at least on paper — may lay claim to the crown as ...
CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. The post Will ...
Of all the performance suffixes you can attach to a BMW, CSL (short for Competition Sport Lightweight) may just be the one that creates the highest of expectations. Hopefully, BMW has brought its ...
YouTube on MSN
Modifying our M3 CSL
When we bought the E46 M3 CSL, we said it was perfect just the way it was, but resisting modifications was never going to ...
Macquarie Group Ltd (ASX: MQG) has downgraded CSL Ltd (ASX: CSL) shares. Let's find out why the broker has made the ...
With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...
CSL Limited, a biotechnology company that produce many of its biological products from plasma, is diversifying its portfolio and its drug pipeline through its largest ever acquisition: the purchase of ...
The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that ...
CSL Behring has struck a deal to buy uniQure’s late-phase hemophilia B gene therapy AMT-061 for $450 million upfront. The agreement will catapult CSL to the front of the race to bring a hemophilia B ...
CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results